Observational Retrospective Multicenter Study to Evaluate Clinical Outcome Variables Change With dapaGLiflozin Treatment Introduced in Patients With T2D uncOntrolled by the Current Therapy in Real Clinical Practice in RussIA
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GLORIA
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 24 May 2017 Planned End Date changed from 28 Apr 2017 to 31 Aug 2017.
- 24 May 2017 Planned primary completion date changed from 28 Apr 2017 to 31 Aug 2017.